METASTATIC COLORECTAL CANCER

This study tests whether adding two targeted drugs (cetuximab and envafolimab) to a stronger chemotherapy cocktail can help people with a specific type of advanced left-side colon cancer that has spread. About 198 adults whose cancer has certain genetic markers (RAS/BRAF wild-typ…

This early-stage trial is testing a new drug called ulixertinib, given together with cetuximab and/or encorafenib, for people with advanced colorectal cancer that has spread and hasn't responded to prior treatments. The main goal is to find the safest dose and check for side effe…

This study tests whether adding a new drug (BNT314) to an existing immunotherapy (BNT327) and chemotherapy can help people with advanced colorectal cancer that didn't respond to first-line treatment. About 482 adults with a specific type of colorectal cancer (MSS/pMMR) will recei…

This study tests a new drug called EMB-01 in people with advanced colorectal cancer that has come back or spread. About 54 adults will be randomly assigned to receive the drug either once a week or on a different schedule. The goal is to see if the drug can shrink tumors and to c…

This early-phase study tests a new treatment for people with metastatic colorectal cancer that has not responded to standard therapies. The treatment uses a two-step process to deliver a radioactive substance directly to cancer cells, aiming to destroy them while sparing healthy …

This study tests an experimental drug called ART0380, taken as a pill, for people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with other chemotherapy drugs (gemcitabine or irinotecan). About 442…

This study is for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C. It tests whether a combination of three drugs (adagrasib, cetuximab, and cemiplimab) can help control the cancer. The goal is to manage the disease, not cure it, and rese…

This early-stage trial tests a new treatment for people with metastatic colorectal or prostate cancer. The treatment uses immune cells (TILs) taken from the patient's own tumor, grown in a lab, and then given back to the patient multiple times. The main goals are to see if it is …

This study tests a new combination of drugs for people with advanced colorectal cancer that has stopped responding to initial treatment. About 30 participants will receive a mix of chemotherapy and targeted therapy to see if it can slow or stop the cancer from growing. The goal i…

This study tests whether combining two drugs, fruquintinib and tislelizumab, can help people with a specific type of advanced colorectal cancer that has not spread to the liver. The cancer must be MSS/pMMR, meaning it does not respond well to standard immunotherapy alone. About 1…

This study tests whether adding two targeted drugs (sotorasib and panitumumab) to standard chemotherapy helps people with a specific type of advanced colorectal cancer (KRAS G12C mutation) live longer without their cancer growing. About 450 people who have not had prior treatment…

This study tests an experimental drug called RBS2418, which is designed to help the immune system fight cancer. It is for adults with advanced colorectal cancer that has spread and is no longer responding to standard treatments. About 150 participants will receive either RBS2418 …

This study tests a new drug called JS212, given together with other cancer medicines, in people whose colorectal cancer has spread (metastatic). The goal is to see if these combinations are safe and can shrink tumors or slow the disease. About 80 adults who have not had prior tre…

This study tests new drug combinations in people with metastatic colorectal cancer that has spread. The goal is to see if these treatments can shrink tumors or slow cancer growth. About 120 adults with measurable disease and good performance status will participate. The trial foc…

This study is for people with advanced colorectal cancer that has a certain genetic makeup (RAS/BRAF wild type) in the tumor but shows a different genetic change (RAS mutation) in a blood test. The goal is to see if a combination of chemotherapy (FOLFIRI) plus a drug called bevac…

This early-phase study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, colorectal, or lung cancer) that have not responded to standard treatments. The drug works by blocking a key cancer growth signal (PI3Kα:RAS). The main goals are to find a safe …

This study tests a new investigational drug called telisotuzumab adizutecan combined with standard chemotherapy and targeted therapies for people with metastatic colorectal cancer (cancer that has spread). About 390 adults will receive either the new drug at different doses or st…

This study looks at how well a biosimilar version of bevacizumab (called Elovie) works and how safe it is for people with advanced colorectal cancer that has spread and cannot be removed by surgery. About 133 adults will be followed as they receive this drug as their first treatm…

This study tests a new combination of chemotherapy drugs (FLIRT) plus bevacizumab for people with a specific genetic type of metastatic colorectal cancer that has not been treated yet. The goal is to see if the treatment is safe and effective at delaying cancer growth. About 27 p…

This study tests whether a three-drug combination (liposomal irinotecan, TAS102, and bevacizumab) can help people with advanced colorectal cancer that has stopped responding to standard treatments. About 50 adults with mismatch repair proficient tumors who have already tried mult…

This study tests an experimental treatment for people with advanced cancers (colon, pancreas, breast, ovarian, and others) that have spread and stopped responding to standard therapy. Doctors take immune cells from a patient's tumor, grow them in a lab, and give them back along w…

This study tests a combination of up to 4 experimental drugs (retifanlimab, TriAdeno vaccine, N-803, and SX-682) in people with metastatic colorectal cancer that has spread and not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors.…

This study compares a new drug, RPH-030, to an existing one, Vectibix, for people with a certain type of advanced colorectal cancer. About 180 participants will receive either drug along with standard chemotherapy. The goal is to see if the new drug works similarly and is as safe…

This study tests several targeted therapies (drugs that attack specific cancer cell features) in people with metastatic colorectal cancer that has spread. Participants receive treatment based on their tumor's unique biomarkers. The goal is to see if these personalized approaches …

This study tests a new drug called precemtabart tocentecan, alone or with bevacizumab, against a standard treatment for metastatic colorectal cancer that has not responded to prior therapies. About 1,020 adults who have already tried up to two prior treatments will participate. T…

This study tests a different chemotherapy drug (trifluridine/tipiracil) for people with metastatic colorectal or gastroesophageal cancer who have a genetic condition (DPD deficiency) that makes standard chemo very toxic. About 73 participants will receive this drug along with oth…

This study tests a drug called enfortumab vedotin in people with advanced colorectal or liver cancer that has spread or cannot be removed. Participants must have already tried at least one standard treatment. The goal is to see if the drug can shrink tumors or slow the disease. A…

This study tests whether ivonescimab, a drug that targets both PD-1 and VEGF, can help control metastatic colorectal cancer that has already been treated. About 90 adults with advanced colon or rectal cancer will receive the drug. The main goal is to check safety and side effects…

This study is testing whether a special PET scan can identify an aggressive form of colorectal cancer called CMS4 without taking tissue samples. About 45 people with colorectal cancer that has spread to the liver will get the scan before surgery. If it works, doctors could use th…

This study aims to create a mindfulness program for people with metastatic colorectal cancer and their partners to help reduce stress. Researchers will interview 48 patients, partners, and clinicians to understand their needs and preferences. The goal is to design a program that …

This study gathers medical information and biological samples from 400 adults with metastatic colorectal cancer that has a specific genetic change called BRAFV600E. The goal is to learn how this cancer is treated in real-world settings and how long people live. No new treatments …

This study watches how doctors treat metastatic colorectal cancer when the first chemotherapy stops working. It will follow 1,000 patients to see which treatments are used next and how well they work. The goal is to learn about real-world treatment patterns and outcomes, not to t…